IMP321 (eftilagimod alpha)

BIOLOGICAL2 trials

Sponsors

Immutep S.A.S., Immutep Australia Pty. Ltd.

Conditions

Adenocarcinoma Breast Stage IVStage III MelanomaStage IV Melanoma

Phase 1

Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma

CompletedNCT02676869

Immutep Australia Pty. Ltd.Stage III Melanoma, Stage IV Melanoma

Start: 2016-04-30End: 2019-12-31Updated: 2019-12-18

Phase 2

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

CompletedNCT02614833

Immutep S.A.S.Adenocarcinoma Breast Stage IV

Start: 2015-12-31End: 2021-05-31Updated: 2021-10-05

Related Papers

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.

Journal of Clinical Oncology2024-06-012 citations

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.

Journal of Clinical Oncology2023-06-01

948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

2021-11-012 citations

Abstract PD14-08: Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients

Cancer Research2021-02-159 citations

Abstract OT1-01-05: AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

Cancer Research2020-02-151 citations

AIPAC: A Phase Iib Study of Eftilagimod Alpha (Imp321 or Lag-3Ig) Added to Weekly Paclitaxel In Patients With Metastatic Breast Cancer

Future Oncology2019-04-1236 citations

Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.

Journal of Clinical Oncology2018-05-2016 citations

Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.

Journal of Clinical Oncology2018-05-2015 citations

AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer.

Journal of Clinical Oncology2018-05-20

Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Interim results from the run-in phase of a placebo controlled randomized phase II.

Journal of Clinical Oncology2017-05-2010 citations